Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Elon Musk made a surprise appearance at a far-right campaign event in Germany where he urged supporters to move beyond their "past guilt". Speaking via video link to a hall of around 4,500 ...

Novo Nordisk is also testing its GLP-1 treatments for benefits beyond diabetes and weight-loss, including Alzheimer's disease and a common type of fatty liver disease known as non-alcoholic ...

Popular GLP-1 medications approved for weight loss, diabetes ... or stomach paralysis. Beyond the gut, people who took GLP-1 medications were also more likely to be diagnosed with problems ...

The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said. Novo Nordisk - which ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss. Published in the journal Nature Medicine, this new study ...

The brand name for the drug semaglutide, created by Danish pharmaceutical company Novo Nordisk to treat Type 2 diabetes, has become known worldwide for its weight loss side effect. Even though it ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Danish pharmaceutical giant Novo Nordisk experienced a remarkable 7.1% surge in its stock price following the release of promising clinical trial results for its new weight loss medication.

Novo Nordisk hopes the new treatment can build on the success of its flagship obesity drug, Wegovy. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market.